Stocks In Focus: OMNOVA Solutions Inc. (NYSE:OMN), Era Group Inc (NYSE:ERA), Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA), Textainer Group Holdings Limited (NYSE:TGH)

Albany, New York (09/25/2014) – OMNOVA Solutions Inc. (NYSE:OMN) posted the net income of $1.8 million in 3Q2014 comparable to $9.0 million in 3Q2013. It accounts for earnings of $0.04 per diluted share comparable to $0.19 per diluted share in 3Q2013. The adjusted income of OMNOVA from continuing operations came at $2.2 million comparable to $8.7 million in the 3Q2013. The sales in chemical product lines rose 2.3% whereas in material product lines decreased 15.4%. The management said that the improvement in Chinese sales, higher carpet and paper margins and growth in oil and gas will result in the sequential profit improvement from 3Q2014 to 4Q2014.

There were some key changes in management of Era Group Inc (NYSE:ERA) management last month. Sten L. Gustafson resigned from the profile of Chief Executive Officer and as director of Era. He left the company on August 29, 2014. He is succeeded by Christopher S. Bradshaw as acting CEO till the time the Board appoints a permanent CEO to replace Gustafson. Bradshaw is the CFO of Era and will continue with his duties with the new responsibility.

Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) provided key updates on ADASUVE® Commercial Activities in European Union. Grupo Ferrer Internacional, S.A. is a commercial partner for Alexza’s ADASUVE in the Latin America, European Union, and the CIS countries. It has distribution agreements with Bioprojet, Galenica SA, AOP Orphan Pharmaceuticals AG and Medivir AB. ADASUVE was launched in Germany in 2013 and now will be available in nine regions in the Ferrer Territory. The roll-out is expected to take place in additional EU countries in this year and next year. France is the major target of for the launch.

Textainer Group Holdings Limited (NYSE:TGH) said that its indirect subsidiary, Textainer Marine Containers II Limited has refinanced its $1.2 Billion Warehouse Financing Facility. There will be three-year revolving period. The interest rate is lowered on the new facility to 1.70% over LIBOR. In case, the facility is not renewed or refinanced, it will end in September 2017.

About the Author

Erica is a graduate of New York University's school of Journalism. She joined US Markets Daily as a general assignment reporter in January of 2008.

Leave A Response